Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Post Quarterly Sales of $2.85 Million

Equities research analysts expect Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) to post sales of $2.85 million for the current quarter, Zacks reports. Two analysts have made estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $3.00 million and the lowest estimate coming in at $2.70 million. Spero Therapeutics posted sales of $7.30 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 61%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $18.49 million for the current financial year, with estimates ranging from $17.80 million to $19.17 million. For the next fiscal year, analysts forecast that the company will report sales of $110.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPROGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.09). Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same quarter last year, the business posted ($0.68) EPS.

Several equities research analysts have weighed in on the stock. HC Wainwright increased their target price on shares of Spero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, March 21st. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 5th.

SPRO opened at $6.11 on Friday. Spero Therapeutics has a one year low of $6.10 and a one year high of $19.87. The company’s 50 day simple moving average is $8.47 and its 200-day simple moving average is $12.67. The stock has a market capitalization of $200.16 million, a P/E ratio of -2.11 and a beta of 1.65.

In related news, major shareholder Aquilo Capital Management, Llc bought 125,000 shares of the business’s stock in a transaction on Monday, January 31st. The shares were purchased at an average price of $11.59 per share, for a total transaction of $1,448,750.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders purchased 225,087 shares of company stock worth $2,507,399 over the last three months. 13.45% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in SPRO. Marshall Wace LLP bought a new stake in Spero Therapeutics in the first quarter valued at $39,000. Wells Fargo & Company MN boosted its holdings in Spero Therapeutics by 122.4% during the second quarter. Wells Fargo & Company MN now owns 39,847 shares of the company’s stock worth $556,000 after purchasing an additional 21,927 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Spero Therapeutics by 10.6% during the third quarter. Janney Montgomery Scott LLC now owns 26,000 shares of the company’s stock worth $479,000 after purchasing an additional 2,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in Spero Therapeutics in the third quarter valued at about $195,000. Finally, New York State Common Retirement Fund boosted its stake in Spero Therapeutics by 42.8% in the third quarter. New York State Common Retirement Fund now owns 71,220 shares of the company’s stock valued at $1,311,000 after acquiring an additional 21,329 shares during the last quarter. Institutional investors and hedge funds own 59.17% of the company’s stock.

Spero Therapeutics Company Profile (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Read More

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.